Get to know our clinical trials
Continuation clinical trial in patients who have completed a previous oncology study with olaparib and who the investigator believes will benefit clinically from continued treatment.
CONTINUED PROVISION OF STUDY TREATMENT TO PATIENTS WHO CONTINUE TO BENEFIT FROM THE DRUG AT THE END OF THEIR CLINICAL TRIAL, WHILE MONITORING SAFETY AND TOLERABILITY.
Technical Summary
- CONTINUATION STUDY IN PATIENTS WHO HAVE COMPLETED A PREVIOUS ONCOLOGY STUDY WITH OLAPARIB AND WHO THE INVESTIGATOR BELIEVES WILL BENEFIT CLINICALLY FROM CONTINUED TREATMENT.
- Code EudraCT: 2019-003777-26
- Protocol number: D0817C00098
- Promoter: Astra Zeneca AB
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.